ArticleFrontiers in neurology2022
Clinical study on the feasibility of new thrombus markers in predicting massive cerebral infarction.
Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Dynamic alterations of thrombotic molecular markers in acute ischemic stroke patients after intravenous thrombolysis: a prospective cohort study.BMC neurology · 2026Article
- Admission Phenotype Clarifies the Apparent Prognostic Contrast Between TOAST Etiologic Subtypes in Large-Core Anterior-Circulation Large-Vessel Occlusion.CNS neuroscience & therapeutics · 2026Article
- Thrombosis biomarkers: utility in early diagnosis and prognosis of severe pneumonia.Thrombosis journal · 2026Article
- Polymeric Fibrous Materials for Procoagulant and Anticoagulant Applications: A Review of Molecular Blood-Material Mechanisms and Strategies.Materials (Basel, Switzerland) · 2026Review
- Molecular biomarkers in dialysis-related thrombosis and anticoagulation monitoring: thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, soluble thrombomodulin, tPA/PAI-1/tPAIC, and Anti-Xa.Frontiers in medicine · 2026Review
- Blood Biomarkers for Large Vessel Occlusions: A Systematic Review.Stroke (Hoboken, N.J.) · 2025Article
- Development and validation of a dynamic nomogram for predicting in-hospital mortality in acute massive cerebral infarction: a retrospective study in a Chinese population.European journal of medical research · 2025Article
- Diagnostic Value of Protein C Depletion in Pathologies Associated with the Activation of the Blood Coagulation System.International journal of molecular sciences · 2025Article
- Predictive Model for Early Neurological Deterioration in Acute Ischemic Stroke Utilizing Novel Thrombotic Biomarkers.Brain and behavior · 2025Article
- Alterations of Hemostatic Molecular Markers During Acute Large Vessel Occlusion Stroke.Journal of the American Heart Association · 2024Article
- [Predictive value of four items of new thrombus markers combined with conventional coagulation tests for thrombosis in antiphospholipid syndrome].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the diagnostic performance of the thrombin-antithrombin complex (TAT), plasmin-α2 plasmin inhibitor complex (PIC), tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC), and thrombomodulin (TM) in the early identification of massive cerebral infarction. Method: A total of 423 patients with cerebral infarction confirmed by imaging examination were divided into the massive cerebral infarction (MCI) group and the non-massive cerebral infarction (NMCI) group. TAT, PIC, t-PAIC, and TM were measured immediately after admission. The diagnostic performance was analyzed by the receiver characteristic operating curve (ROC). Result: The median plasma concentrations of TAT, PIC, and t-PAIC in patients with MCI at early onset were 5.10 ng/ml, 1.11 μg/ml, and 8.80 ng/ml, respectively, which were higher than those in patients with NMCI (2.20 ng/ml, 0.59 μg/ml, and 7.35 ng/ml), and the difference was statistically significant ( Conclusion: The detection of PIC, TAT, t-PAIC, and TM is a comprehensive assessment of vascular endothelial damage and activation of the coagulation and fibrinolytic systems and has diagnostic value for early identification of patients with MCI, which, together with its ease of detection, can be used as a plasma marker for early identification of large vessel occlusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.